This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin prick tests and higher baseline lung function have better treatment outcomes, highlighting the value of personalised treatment strategies.
Keywords: T2‐high phenotype; anti‐IL5; machine learning; mepolizumab; prediction of clinical response; real‐life study; remission; super‐response.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.